Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ANAB with free AI briefings, catalyst countdowns, and dilution alerts.

ANAB · ANAPTYSBIO, INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$212.7M Cash on Hand
36mo Cash Runway
Follow ANAB by email Get an email when ANAB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ANAB, unsubscribe in one click. Privacy

💊 Upcoming FDA Decisions

PDUFA DateDrugIndicationTypePoA
2026-12-12 Quimilza (imsidolimab) (Vanda) generalized pustular psoriasis (GPP) BLA 67%

PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →

📣 What ANAB Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
ANB032 Atopic Dermatitis Eczema Phase 2 · NCT05935085 Terminated
Etokimab Eosinophilic Asthma Phase 2 · NCT03469934 Completed
Mometasone Furoate Nasal Spray, 50 mcg Chronic Rhinosinusitis Phase 2 · NCT03614923 Completed
Rosnilimab Rheumatoid Arthritis Phase 2 · NCT06041269 Active not recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ANAB holds $212.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $17.7M/quarter from operations, an estimated runway of 36 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 40 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ANAB files for a raise →

👥 Who Owns ANAB

Insiders 2.2% Institutions (317 holders) 97.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Daniel Faga
President, CEO, Director · +2.33M options
Insider 495,965 1.66% 2026-03-25
Paul F. Lizzul
Chief Medical Officer · +71,242 options
Insider 42,088 0.14% 2026-01-07
John P. Schmid
Director · +220,140 options
Insider 37,652 0.13% 2026-06-15
Dennis Mulroy
CHIEF FINANCIAL OFFICER · +49,100 options
Insider 21,852 0.07% 2026-01-07
John A Orwin
Director · +111,990 options
Insider 17,995 0.06% 2026-09-15
Eric J Loumeau
CHIEF LEGAL OFFICER · +75,862 options
Insider 12,835 0.04% 2026-02-11
Hollings Renton
Director · +230,140 options
Insider 10,995 0.04% 2026-10-01
Magda Marquet
Director · +9,500 options
Insider 9,930 0.03% 2026-01-15

Share count 29,895,244 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-10-19 Jemperli NDA -15.4% +5.6% +4.6%
2026-06-30 — NDA +15.7% +2.3% +2.1%

Browse all historical PDUFA outcomes →

Get the full ANAB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ANAB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.